Koreny Maria, Riedmüller Eva, Nikfardjam Mariam, Siostrzonek Peter, Müllner Marcus
Department of Emergency Medicine, University of Vienna, Vienna General Hospital, Vienna, Austria.
JAMA. 2004 Jan 21;291(3):350-7. doi: 10.1001/jama.291.3.350.
Arterial puncture closing devices (APCDs) were developed to replace standard compression at the puncture site and to shorten bed rest following percutaneous coronary intervention.
To assess the safety and efficacy of APCDs (Angioseal, Vasoseal, Duett, Perclose, Techstar, Prostar) compared with standard manual compression in patients undergoing coronary angiography or percutaneous vascular interventions.
A systematic literature search of MEDLINE (1966-January 2003), EMBASE (1989-January 2003), PASCAL (1996-January 2003), BIOSIS (1990-January 2003), and CINHAL (1982-January 2003) databases and the Cochrane Central Register of Controlled Trials for relevant articles in any language.
Included randomized controlled trials reporting vascular complications at the puncture site (hematoma, bleeding, arteriovenous fistula, pseudoaneurysm) and efficacy (time to hemostasis, time to ambulation, time to discharge from hospital).
Two reviewers abstracted the data independently and in duplicate. Disagreements were resolved by discussion among at least 3 reviewers. The most important criteria were adequacy of allocation concealment, whether the analysis was according to the intention-to-treat principle, and if person assessing the outcome was blinded to intervention group. Random-effects models were used to pool the data.
Thirty trials met the selection criteria and included up to 4000 patients. When comparing any APCD with standard compression, the relative risk (RR) of groin hematoma was 1.14 (95% confidence interval [CI], 0.86-1.51; P =.35); bleeding, 1.48 (95% CI, 0.88-2.48; P =.14); developing an arteriovenous fistula, 0.83 (95% CI, 0.23-2.94; P =.77); and developing a pseudoaneurysm at the puncture site, 1.19 (95% CI, 0.75-1.88; P =.46). Time to hemostasis was shorter in the group with APCD compared with standard compression (mean difference, 17 minutes; range, 14-19 minutes), but there was a high degree of heterogeneity among studies. Only 2 studies explicitly reported allocation concealment, blinded outcome assessment, and intention-to-treat analysis. When limiting analyses to only trials that used explicit intention-to-treat approaches, APCDs were associated with a higher risk of hematoma (RR, 1.89; 95% CI, 1.13-3.15) and a higher risk of pseudoaneurysm (RR, 5.40; 95% CI, 1.21-24.5).
Based on this meta-analysis of 30 randomized trials, many of poor methodological quality, there is only marginal evidence that APCDs are effective and there is reason for concern that these devices may increase the risk of hematoma and pseudoaneurysm.
动脉穿刺闭合装置(APCDs)的研发旨在取代穿刺部位的标准压迫止血法,并缩短经皮冠状动脉介入治疗后的卧床休息时间。
评估在接受冠状动脉造影或经皮血管介入治疗的患者中,与标准手动压迫止血法相比,APCDs(Angioseal、Vasoseal、Duett、Perclose、Techstar、Prostar)的安全性和有效性。
对MEDLINE(1966年至2003年1月)、EMBASE(1989年至2003年1月)、PASCAL(1996年至2003年1月)、BIOSIS(1990年至2003年1月)和CINHAL(1982年至2003年1月)数据库以及Cochrane对照试验中心注册库进行系统文献检索,以查找任何语言的相关文章。
纳入报告穿刺部位血管并发症(血肿形成、出血、动静脉瘘、假性动脉瘤)和有效性(止血时间、下床活动时间、出院时间)的随机对照试验。
两名评价者独立且重复地提取资料。分歧通过至少三名评价者的讨论解决。最重要的标准是分配隐藏的充分性、分析是否根据意向性分析原则进行,以及结果评估者是否对干预组不知情。采用随机效应模型汇总资料。
30项试验符合选择标准,纳入患者多达4000例。将任何APCD与标准压迫止血法进行比较时,腹股沟血肿的相对危险度(RR)为1.14(95%可信区间[CI],0.86 - 1.51;P = 0.35);出血的RR为1.48(95%CI,0.88 - 2.48;P = 0.14);发生动静脉瘘的RR为0.83(95%CI,0.23 - 2.94;P = 0.77);穿刺部位发生假性动脉瘤的RR为1.19(95%CI,0.75 - 1.88;P = 0.46)。与标准压迫止血法相比,APCD组的止血时间更短(平均差值为17分钟;范围为14 - 19分钟),但研究间存在高度异质性。仅有2项研究明确报告了分配隐藏、盲法结果评估和意向性分析。当仅将分析限于采用明确意向性分析方法的试验时,APCDs与更高的血肿风险(RR,1.89;95%CI,1.13 - 3.15)和更高的假性动脉瘤风险(RR,5.40;95%CI,1.21 - 24.5)相关。
基于对30项随机试验的这项荟萃分析,其中许多试验的方法学质量较差,仅有少量证据表明APCDs有效,且有理由担心这些装置可能增加血肿和假性动脉瘤的风险。